JP2019527229A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527229A5 JP2019527229A5 JP2019504021A JP2019504021A JP2019527229A5 JP 2019527229 A5 JP2019527229 A5 JP 2019527229A5 JP 2019504021 A JP2019504021 A JP 2019504021A JP 2019504021 A JP2019504021 A JP 2019504021A JP 2019527229 A5 JP2019527229 A5 JP 2019527229A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- acid sequence
- protein
- cdna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 29
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 18
- 235000003704 aspartic acid Nutrition 0.000 claims 18
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 17
- 239000002299 complementary DNA Substances 0.000 claims 16
- 229920001184 polypeptide Polymers 0.000 claims 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims 16
- 239000000523 sample Substances 0.000 claims 14
- 101001039301 Homo sapiens Probable G-protein coupled receptor 156 Proteins 0.000 claims 13
- 102100041015 Probable G-protein coupled receptor 156 Human genes 0.000 claims 13
- 108020004705 Codon Proteins 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 239000000935 antidepressant agent Substances 0.000 claims 8
- 230000035772 mutation Effects 0.000 claims 8
- 230000001430 anti-depressive effect Effects 0.000 claims 7
- 229940005513 antidepressants Drugs 0.000 claims 7
- 230000000295 complement effect Effects 0.000 claims 5
- 235000018102 proteins Nutrition 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 101100505306 Homo sapiens GPR156 gene Proteins 0.000 claims 4
- 150000001413 amino acids Chemical group 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 3
- 208000020401 Depressive disease Diseases 0.000 claims 3
- 101000887490 Homo sapiens Guanine nucleotide-binding protein G(z) subunit alpha Proteins 0.000 claims 3
- 201000003104 endogenous depression Diseases 0.000 claims 3
- 102000052301 human GNAZ Human genes 0.000 claims 3
- 208000024714 major depressive disease Diseases 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000013566 allergen Substances 0.000 claims 2
- 239000007850 fluorescent dye Substances 0.000 claims 2
- 102000034287 fluorescent proteins Human genes 0.000 claims 2
- 108091006047 fluorescent proteins Proteins 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 230000000994 depressogenic effect Effects 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 238000002493 microarray Methods 0.000 claims 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023019464A JP2023071704A (ja) | 2016-07-28 | 2023-02-10 | Ｇｐｒ１５６変異体及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662367973P | 2016-07-28 | 2016-07-28 | |
| US62/367,973 | 2016-07-28 | ||
| PCT/US2017/044321 WO2018022967A1 (en) | 2016-07-28 | 2017-07-28 | Gpr156 variants and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023019464A Division JP2023071704A (ja) | 2016-07-28 | 2023-02-10 | Ｇｐｒ１５６変異体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527229A JP2019527229A (ja) | 2019-09-26 |
| JP2019527229A5 true JP2019527229A5 (enExample) | 2020-09-03 |
| JP7556688B2 JP7556688B2 (ja) | 2024-09-26 |
Family
ID=59649989
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019504021A Active JP7556688B2 (ja) | 2016-07-28 | 2017-07-28 | Ｇｐｒ１５６変異体及びその使用 |
| JP2023019464A Pending JP2023071704A (ja) | 2016-07-28 | 2023-02-10 | Ｇｐｒ１５６変異体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023019464A Pending JP2023071704A (ja) | 2016-07-28 | 2023-02-10 | Ｇｐｒ１５６変異体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10266582B2 (enExample) |
| EP (2) | EP4230648A3 (enExample) |
| JP (2) | JP7556688B2 (enExample) |
| KR (2) | KR102661616B1 (enExample) |
| CN (1) | CN109563516B (enExample) |
| AU (1) | AU2017302611B2 (enExample) |
| CA (1) | CA3032124A1 (enExample) |
| DK (1) | DK3491014T5 (enExample) |
| IL (1) | IL264473A (enExample) |
| MX (2) | MX2019001084A (enExample) |
| NZ (1) | NZ751010A (enExample) |
| SG (1) | SG11201900738YA (enExample) |
| WO (1) | WO2018022967A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4230648A3 (en) * | 2016-07-28 | 2023-10-18 | Regeneron Pharmaceuticals, Inc. | Gpr156 variants and uses thereof |
| SG11202001754RA (en) | 2017-09-06 | 2020-03-30 | Regeneron Pharma | Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof |
| PL3505157T3 (pl) | 2017-12-29 | 2022-04-11 | Celon Pharma S.A. | Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| AU2020209184A1 (en) * | 2019-01-17 | 2021-07-08 | Regeneron Pharmaceuticals, Inc. | A rodent model of mood disorders |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5294533A (en) | 1988-07-05 | 1994-03-15 | Baylor College Of Medicine | Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria |
| US5135917A (en) | 1990-07-12 | 1992-08-04 | Nova Pharmaceutical Corporation | Interleukin receptor expression inhibiting antisense oligonucleotides |
| US5271941A (en) | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
| US5786138A (en) | 1993-01-29 | 1998-07-28 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Hyperstabilizing antisense nucleic acid binding agents |
| DE69425890D1 (de) | 1993-06-04 | 2000-10-19 | Us Health | Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide |
| US5578716A (en) | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
| US5641754A (en) | 1994-01-10 | 1997-06-24 | The Board Of Regents Of The University Of Nebraska | Antisense oligonucleotide compositions for selectively killing cancer cells |
| JPH10503934A (ja) | 1994-08-09 | 1998-04-14 | ノバルティス アクチエンゲゼルシャフト | 抗腫瘍性アンチセンスオリゴヌクレオチド |
| US5856103A (en) | 1994-10-07 | 1999-01-05 | Board Of Regents The University Of Texas | Method for selectively ranking sequences for antisense targeting |
| US5994320A (en) | 1995-02-06 | 1999-11-30 | Regents Of The University Of Minnesota | Antisense oligonucleotides and methods for treating central nervous system tumors |
| IT1275862B1 (it) | 1995-03-03 | 1997-10-24 | Consiglio Nazionale Ricerche | Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento |
| US6040296A (en) | 1995-06-07 | 2000-03-21 | East Carolina University | Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation |
| WO1997014709A1 (en) | 1995-10-13 | 1997-04-24 | F. Hoffmann-La Roche Ag | Antisense oligomers |
| CA2236825A1 (en) | 1995-11-21 | 1997-05-29 | Icn Pharmaceuticals, Inc. | Inhibition of tumor growth by antisense oligonucleotides for il-8 and il-8 receptor |
| US5998602A (en) | 1996-02-15 | 1999-12-07 | The Cleveland Clinic Fouindation And Government | RNase L activators and antisense oligonucleotides effective to treat RSV infections |
| US5955590A (en) | 1996-07-15 | 1999-09-21 | Worcester Foundation For Biomedical Research | Conjugates of minor groove DNA binders with antisense oligonucleotides |
| US6046004A (en) | 1997-02-27 | 2000-04-04 | Lorne Park Research, Inc. | Solution hybridization of nucleic acids with antisense probes having modified backbones |
| JPH1142091A (ja) | 1997-07-25 | 1999-02-16 | Toagosei Co Ltd | アンチセンス核酸化合物 |
| US6046319A (en) | 1997-10-22 | 2000-04-04 | University Technologies International, Inc. | Antisense oligodeoxynucleotides regulating expression of TNF-α |
| US6551795B1 (en) | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| US6007995A (en) | 1998-06-26 | 1999-12-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of TNFR1 expression |
| US6013522A (en) | 1999-02-23 | 2000-01-11 | Isis Pharmaceuticals Inc. | Antisense inhibition of human Smad1 expression |
| US6025198A (en) | 1999-06-25 | 2000-02-15 | Isis Pharmaceuticals Inc. | Antisense modulation of Ship-2 expression |
| AU6343400A (en) * | 1999-07-09 | 2001-01-30 | Genaissance Pharmaceuticals, Inc. | Drug target isogenes: polymorphisms in the osteoclastogenesis inhibitory factor gene |
| US6033910A (en) | 1999-07-19 | 2000-03-07 | Isis Pharmaceuticals Inc. | Antisense inhibition of MAP kinase kinase 6 expression |
| AU2001255397A1 (en) * | 2000-04-18 | 2001-10-30 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the ugt1a1 gene |
| JP2006513702A (ja) | 2002-09-09 | 2006-04-27 | ヌラ インコーポレーティッド | Ｇタンパク質共役受容体およびその使用 |
| DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
| EP1745018A1 (en) * | 2004-04-29 | 2007-01-24 | Merck & Co., Inc. | Azetidine glycine transporter inhibitors |
| EP2091556B1 (en) | 2006-11-15 | 2018-07-25 | Omeros Corporation | Non-human animal comprising a mutation in the sreb2/gpr85 gene as animal model of metabolic disease |
| AU2013262709A1 (en) * | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating MECP2 expression |
| MY189533A (en) | 2012-05-25 | 2022-02-16 | Univ California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| AU2013355214B2 (en) | 2012-12-06 | 2017-06-15 | Sigma-Aldrich Co. Llc | Crispr-based genome modification and regulation |
| SG11201805112WA (en) * | 2015-12-21 | 2018-07-30 | Bayer Oy | A method of manufacturing a vaginal ring |
| EP4230648A3 (en) | 2016-07-28 | 2023-10-18 | Regeneron Pharmaceuticals, Inc. | Gpr156 variants and uses thereof |
-
2017
- 2017-07-28 EP EP23162215.0A patent/EP4230648A3/en not_active Withdrawn
- 2017-07-28 CN CN201780048589.4A patent/CN109563516B/zh active Active
- 2017-07-28 JP JP2019504021A patent/JP7556688B2/ja active Active
- 2017-07-28 AU AU2017302611A patent/AU2017302611B2/en active Active
- 2017-07-28 CA CA3032124A patent/CA3032124A1/en active Pending
- 2017-07-28 MX MX2019001084A patent/MX2019001084A/es unknown
- 2017-07-28 SG SG11201900738YA patent/SG11201900738YA/en unknown
- 2017-07-28 EP EP17754224.8A patent/EP3491014B1/en active Active
- 2017-07-28 DK DK17754224.8T patent/DK3491014T5/da active
- 2017-07-28 NZ NZ751010A patent/NZ751010A/en unknown
- 2017-07-28 US US15/662,689 patent/US10266582B2/en active Active
- 2017-07-28 KR KR1020197001965A patent/KR102661616B1/ko active Active
- 2017-07-28 KR KR1020247005755A patent/KR20240027874A/ko not_active Ceased
- 2017-07-28 WO PCT/US2017/044321 patent/WO2018022967A1/en not_active Ceased
-
2019
- 2019-01-25 MX MX2024013403A patent/MX2024013403A/es unknown
- 2019-01-27 IL IL264473A patent/IL264473A/en unknown
- 2019-03-15 US US16/354,563 patent/US10562953B2/en active Active
-
2020
- 2020-01-03 US US16/733,663 patent/US11155598B2/en not_active Expired - Fee Related
-
2021
- 2021-09-23 US US17/483,047 patent/US20220073589A1/en not_active Abandoned
-
2023
- 2023-02-10 JP JP2023019464A patent/JP2023071704A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527229A5 (enExample) | ||
| JP6559227B2 (ja) | 細胞透過性の改善のための進化型巨大分子伝達ドメイン（ａｄｖａｎｃｅｄ ｍａｃｒｏｍｏｌｅｃｕｌｅ ｔｒａｎｓｄｕｃｔｉｏｎ ｄｏｍａｉｎ）（ＡＭＴＤ）配列、それをコードするポリヌクレオチド、それを含むＡＭＴＤの固有の特性を同定する方法、それを含むＡＭＴＤ配列を開発する方法 | |
| JP2011501942A5 (enExample) | ||
| Generous et al. | Identification of putative interactions between swine and human influenza A virus nucleoprotein and human host proteins | |
| Le May et al. | The N terminus of Rift Valley fever virus nucleoprotein is essential for dimerization | |
| JP2005518212A5 (enExample) | ||
| JP2013526840A5 (enExample) | ||
| CN101440128A (zh) | 人脑胶质瘤中差异表达的蛋白及其用途 | |
| JP2013502217A5 (enExample) | ||
| Krishnan et al. | A molecular dynamics study on RAGE-Aβ42 interaction and the influence of G82S RAGE polymorphism on Aβ interaction | |
| JP2008509659A5 (enExample) | ||
| US9085641B2 (en) | Peptides regulating the surface expression of the T cell receptor | |
| To | Interaction Study of Influenza RNA Polymerase Subunit PB2 and Nucleoprotein | |
| CN102329377B (zh) | 狂犬病病毒优势表位肽抗原及其用途 | |
| Garigliany et al. | Human/bovine chimeric MxA-like GTPases reveal a contribution of N-terminal domains to the magnitude of anti-influenza A activity | |
| CN103954601A (zh) | 一种mdm2拮抗剂的检验试剂盒及其制备方法 | |
| JP4140951B2 (ja) | 転写制御因子ｚｈｘ３ | |
| JP2013545440A (ja) | マカカ・ファシキュラリス（Ｍａｃａｃａｆａｓｃｉｃｕｌａｒｉｓ）ＣＣＬ１７ | |
| JP7709383B2 (ja) | 抗体の精製を促進するための機能化ｕｂｘタンパク質物質 | |
| RU2020112313A (ru) | Варианты члена 1 семейства 14 переносчиков растворенных веществ (slc14a1)и их применение | |
| WO2002040523A1 (en) | A NOVEL POLYPEPTIDE-HOMO GLUTARYL- CoA DEHYDROGENASE 15.51 AND POLYNUCLEOTIDE ENCODING SAID POLYPEPTIDE | |
| IL272940B1 (en) | Variants linked to the interleukin-1 immunoglobulin-single receptor and their uses | |
| WO2001048221A1 (fr) | Nouveau polypeptide, colipase 12, et polynucleotide codant pour ce polypeptide | |
| WO2002000866A1 (en) | A new polypeptide- human i class aminoacyl-trna synthetase 10 and the polynucleotide encoding it | |
| CN102212141A (zh) | 一种融合蛋白tat-nanog及其编码基因与应用 |